Pfizer Inc. (PFE) EV/Sales Ratio: 3.31x
Is Pfizer Inc.’s EV/Sales ratio high or low?
Pfizer Inc.'s EV/Sales ratio of 3.31x is in line with its 5-year average of 3.63x, near the low end of its 5-year range (2.50x–6.68x).
The EV/Sales ratio for Pfizer Inc. (PFE) is 3.31x as of Wednesday, June 10, 2026. It is above its 12-month average by 0.38% (3.30x).
PFE EV/Sales Ratio Chart
PFE Average EV/Sales Ratio Chart
PFE Current vs Average EV/Sales Ratio Chart
PFE EV/Sales Ratio Metrics
EV/SALES RATIO
3.31x
EV/SALES RATIO AVG TTM
3.30x
EV/SALES RATIO AVG 3Y
3.43x
EV/SALES RATIO AVG 5Y
3.63x
EV/SALES RATIO AVG 10Y
4.30x
EV/SALES RATIO AVG 15Y
4.18x
EV/SALES RATIO AVG 20Y
3.91x
CURRENT VS TTM AVG
+0.38%
CURRENT VS 3Y AVG
-3.39%
CURRENT VS 5Y AVG
-8.90%
CURRENT VS 10Y AVG
-22.93%
CURRENT VS 15Y AVG
-20.82%
CURRENT VS 20Y AVG
-15.38%
PFE Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $146.36B | 3.31x | 3.30x | 3.43x | 3.63x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 13.87x | 18.43x | 19.52x | 18.69x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 5.62x | 6.02x | 4.98x | 4.64x |
| Abbott Laboratories (ABT) | $154.66B | 4.04x | 4.94x | 5.00x | 4.98x |
| Danaher Corporation (DHR) | $130.25B | 5.81x | 6.63x | 7.16x | 7.00x |
| CVS Health Corporation (CVS) | $125.16B | 0.48x | 0.44x | 0.43x | 0.51x |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 3.08x | 2.99x | 3.12x | 3.48x |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 4.87x | 5.13x | 5.38x | 5.62x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 8.85x | 9.44x | 10.00x | 9.07x |
| Amgen Inc. (AMGN) | $183.75B | 6.19x | 6.19x | 6.53x | 6.39x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Pfizer Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Pfizer Inc. (PFE)?
- The EV/Sales ratio for PFE stock is 3.31x.
- Is Pfizer Inc.'s EV/Sales ratio high or low?
- Pfizer Inc.'s EV/Sales ratio of 3.31x is in line with its 5-year average of 3.63x, near the low end of its 5-year range (2.50x–6.68x).
- What is the TTM average EV/Sales ratio for Pfizer Inc. (PFE)?
- The TTM average EV/Sales ratio for PFE stock is 3.30x.
- What is the 3Y average EV/Sales ratio for Pfizer Inc. (PFE)?
- The 3Y average EV/Sales ratio for PFE stock is 3.43x.
- What is the 5Y average EV/Sales ratio for Pfizer Inc. (PFE)?
- The 5Y average EV/Sales ratio for PFE stock is 3.63x.
- What is the 10Y average EV/Sales ratio for Pfizer Inc. (PFE)?
- The 10Y average EV/Sales ratio for PFE stock is 4.30x.
- What is the 15Y average EV/Sales ratio for Pfizer Inc. (PFE)?
- The 15Y average EV/Sales ratio for PFE stock is 4.18x.
- What is the 20Y average EV/Sales ratio for Pfizer Inc. (PFE)?
- The 20Y average EV/Sales ratio for PFE stock is 3.91x.
Pfizer Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-10 | 3.31x |
| 2026-06-09 | 3.32x |
| 2026-06-08 | 3.31x |
| 2026-06-05 | 3.35x |
| 2026-06-04 | 3.32x |
| 2026-06-03 | 3.28x |
| 2026-06-02 | 3.30x |
| 2026-06-01 | 3.31x |
| 2026-05-29 | 3.36x |
| 2026-05-28 | 3.36x |
| 2026-05-27 | 3.36x |
| 2026-05-26 | 3.33x |
| 2026-05-22 | 3.34x |
| 2026-05-21 | 3.34x |
| 2026-05-20 | 3.33x |
| 2026-05-19 | 3.31x |
| 2026-05-18 | 3.28x |
| 2026-05-15 | 3.28x |
| 2026-05-14 | 3.32x |
| 2026-05-13 | 3.34x |
| 2026-05-12 | 3.33x |
| 2026-05-11 | 3.33x |
| 2026-05-08 | 3.32x |
| 2026-05-07 | 3.39x |
| 2026-05-06 | 3.39x |
| 2026-05-05 | 3.39x |
| 2026-05-04 | 3.45x |
| 2026-05-01 | 3.45x |
| 2026-04-30 | 3.49x |
| 2026-04-29 | 3.45x |
| 2026-04-28 | 3.47x |
| 2026-04-27 | 3.49x |
| 2026-04-24 | 3.51x |
| 2026-04-23 | 3.48x |
| 2026-04-22 | 3.49x |
| 2026-04-21 | 3.54x |
| 2026-04-20 | 3.56x |
| 2026-04-17 | 3.56x |
| 2026-04-16 | 3.53x |
| 2026-04-15 | 3.53x |
| 2026-04-14 | 3.52x |
| 2026-04-13 | 3.54x |
| 2026-04-10 | 3.51x |
| 2026-04-09 | 3.53x |
| 2026-04-08 | 3.56x |
| 2026-04-07 | 3.52x |
| 2026-04-06 | 3.59x |
| 2026-04-02 | 3.63x |
| 2026-04-01 | 3.65x |
| 2026-03-31 | 3.61x |
| 2026-03-30 | 3.58x |
| 2026-03-27 | 3.52x |
| 2026-03-26 | 3.56x |
| 2026-03-25 | 3.54x |
| 2026-03-24 | 3.51x |
| 2026-03-23 | 3.49x |
| 2026-03-20 | 3.51x |
| 2026-03-19 | 3.55x |
| 2026-03-18 | 3.54x |
| 2026-03-17 | 3.55x |
| 2026-03-16 | 3.48x |
| 2026-03-13 | 3.47x |
| 2026-03-12 | 3.50x |
| 2026-03-11 | 3.54x |
| 2026-03-10 | 3.53x |
| 2026-03-09 | 3.50x |
| 2026-03-06 | 3.52x |
| 2026-03-05 | 3.48x |
| 2026-03-04 | 3.48x |
| 2026-03-03 | 3.47x |
| 2026-03-02 | 3.54x |
| 2026-02-27 | 3.57x |
| 2026-02-26 | 3.52x |
| 2026-02-25 | 3.43x |
| 2026-02-24 | 3.43x |
| 2026-02-23 | 3.42x |
| 2026-02-20 | 3.39x |
| 2026-02-19 | 3.41x |
| 2026-02-18 | 3.45x |
| 2026-02-17 | 3.45x |
| 2026-02-13 | 3.47x |
| 2026-02-12 | 3.46x |
| 2026-02-11 | 3.49x |
| 2026-02-10 | 3.47x |
| 2026-02-09 | 3.42x |
| 2026-02-06 | 3.44x |
| 2026-02-05 | 3.37x |
| 2026-02-04 | 3.40x |
| 2026-02-03 | 3.31x |
| 2026-02-02 | 3.39x |
| 2026-01-30 | 3.37x |
| 2026-01-29 | 3.34x |
| 2026-01-28 | 3.32x |
| 2026-01-27 | 3.37x |
| 2026-01-26 | 3.32x |
| 2026-01-23 | 3.30x |
| 2026-01-22 | 3.34x |
| 2026-01-21 | 3.32x |
| 2026-01-20 | 3.28x |
| 2026-01-16 | 3.30x |
| 2026-01-15 | 3.32x |
| 2026-01-14 | 3.29x |
| 2026-01-13 | 3.25x |
| 2026-01-12 | 3.26x |
| 2026-01-09 | 3.28x |
| 2026-01-08 | 3.26x |
| 2026-01-07 | 3.26x |
| 2026-01-06 | 3.28x |
| 2026-01-05 | 3.25x |
| 2026-01-02 | 3.25x |
| 2025-12-31 | 3.23x |
| 2025-12-30 | 3.24x |
| 2025-12-29 | 3.24x |
| 2025-12-26 | 3.24x |
| 2025-12-24 | 3.24x |
| 2025-12-23 | 3.23x |
| 2025-12-22 | 3.26x |
| 2025-12-19 | 3.25x |
| 2025-12-18 | 3.24x |
| 2025-12-17 | 3.24x |
| 2025-12-16 | 3.28x |
| 2025-12-15 | 3.37x |
| 2025-12-12 | 3.31x |
| 2025-12-11 | 3.31x |
| 2025-12-10 | 3.31x |
| 2025-12-09 | 3.27x |
| 2025-12-08 | 3.31x |
| 2025-12-05 | 3.33x |
| 2025-12-04 | 3.30x |
| 2025-12-03 | 3.29x |
| 2025-12-02 | 3.25x |
| 2025-12-01 | 3.26x |
| 2025-11-28 | 3.30x |
| 2025-11-26 | 3.30x |
| 2025-11-25 | 3.30x |
| 2025-11-24 | 3.26x |
| 2025-11-21 | 3.24x |
| 2025-11-20 | 3.18x |
| 2025-11-19 | 3.23x |
| 2025-11-18 | 3.28x |
| 2025-11-17 | 3.24x |
| 2025-11-14 | 3.24x |
| 2025-11-13 | 3.31x |
| 2025-11-12 | 3.32x |
| 2025-11-11 | 3.28x |
| 2025-11-10 | 3.18x |
| 2025-11-07 | 3.18x |
| 2025-11-06 | 3.22x |
| 2025-11-05 | 3.20x |
| 2025-11-04 | 3.17x |
| 2025-11-03 | 3.15x |
| 2025-10-31 | 3.15x |
| 2025-10-30 | 3.11x |
| 2025-10-29 | 3.11x |
| 2025-10-28 | 3.13x |
| 2025-10-27 | 3.16x |
| 2025-10-24 | 3.16x |
| 2025-10-23 | 3.15x |
| 2025-10-22 | 3.15x |
| 2025-10-21 | 3.16x |
| 2025-10-20 | 3.15x |
| 2025-10-17 | 3.13x |
| 2025-10-16 | 3.11x |
| 2025-10-15 | 3.12x |
| 2025-10-14 | 3.13x |
| 2025-10-13 | 3.15x |
| 2025-10-10 | 3.16x |
| 2025-10-09 | 3.20x |
| 2025-10-08 | 3.24x |
| 2025-10-07 | 3.29x |
| 2025-10-06 | 3.31x |
| 2025-10-03 | 3.39x |
| 2025-10-02 | 3.36x |
| 2025-10-01 | 3.37x |
| 2025-09-30 | 3.22x |
| 2025-09-29 | 3.07x |
| 2025-09-26 | 3.07x |
| 2025-09-25 | 3.05x |
| 2025-09-24 | 3.10x |
| 2025-09-23 | 3.10x |
| 2025-09-22 | 3.09x |
| 2025-09-19 | 3.09x |
| 2025-09-18 | 3.10x |
| 2025-09-17 | 3.09x |
| 2025-09-16 | 3.08x |
| 2025-09-15 | 3.09x |
| 2025-09-12 | 3.08x |
| 2025-09-11 | 3.16x |
| 2025-09-10 | 3.14x |
| 2025-09-09 | 3.15x |
| 2025-09-08 | 3.14x |
| 2025-09-05 | 3.17x |
| 2025-09-04 | 3.14x |
| 2025-09-03 | 3.16x |
| 2025-09-02 | 3.18x |
| 2025-08-29 | 3.16x |
| 2025-08-28 | 3.14x |
| 2025-08-27 | 3.18x |
| 2025-08-26 | 3.17x |
| 2025-08-25 | 3.19x |
| 2025-08-22 | 3.26x |
| 2025-08-21 | 3.24x |
| 2025-08-20 | 3.21x |
| 2025-08-19 | 3.21x |
| 2025-08-18 | 3.18x |
| 2025-08-15 | 3.19x |
| 2025-08-14 | 3.19x |
| 2025-08-13 | 3.19x |
| 2025-08-12 | 3.15x |
| 2025-08-11 | 3.14x |
| 2025-08-08 | 3.14x |
| 2025-08-07 | 3.11x |
| 2025-08-06 | 3.08x |
| 2025-08-05 | 3.15x |
| 2025-08-04 | 3.11x |
| 2025-08-01 | 3.11x |
| 2025-07-31 | 3.09x |
| 2025-07-30 | 3.13x |
| 2025-07-29 | 3.18x |
| 2025-07-28 | 3.18x |
| 2025-07-25 | 3.22x |
| 2025-07-24 | 3.28x |
| 2025-07-23 | 3.28x |
| 2025-07-22 | 3.26x |
| 2025-07-21 | 3.18x |
| 2025-07-18 | 3.20x |
| 2025-07-17 | 3.21x |
| 2025-07-16 | 3.21x |
| 2025-07-15 | 3.21x |
| 2025-07-14 | 3.28x |
| 2025-07-11 | 3.30x |
| 2025-07-10 | 3.31x |
| 2025-07-09 | 3.29x |
| 2025-07-08 | 3.30x |
| 2025-07-07 | 3.27x |
| 2025-07-03 | 3.28x |
| 2025-07-02 | 3.27x |
| 2025-07-01 | 3.25x |
| 2025-06-30 | 3.17x |
| 2025-06-27 | 3.17x |
| 2025-06-26 | 3.17x |
| 2025-06-25 | 3.18x |
| 2025-06-24 | 3.18x |
| 2025-06-23 | 3.16x |
| 2025-06-20 | 3.15x |
| 2025-06-18 | 3.14x |
| 2025-06-17 | 3.15x |
| 2025-06-16 | 3.19x |
| 2025-06-13 | 3.20x |
| 2025-06-12 | 3.23x |
| 2025-06-11 | 3.20x |
| 2025-06-10 | 3.18x |
| 2025-06-09 | 3.15x |
| 2025-06-06 | 3.09x |
| 2025-06-05 | 3.07x |
| 2025-06-04 | 3.10x |
| 2025-06-03 | 3.09x |
| 2025-06-02 | 3.10x |
| 2025-05-30 | 3.11x |
| 2025-05-29 | 3.10x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla